Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Wheatgrass Extract (Mugineic Acid): An Inexpensive and Effective Iron Chelator in Patients with Myelodysyplastic Syndromes

David P. Steensma, MD

Blood (2017) 130 (Supplement 1): 5305.

https://doi.org/10.1182/blood.V130.Suppl_1.5305.5305

Published: 2017

Journal Articles

Impact of Age and Type of Underlying Disease on Long-Term Safety and Efficacy in Patients with Transfusional Hemosiderosis Treated with Deferasirox: Results from a 3-Year Non-Interventional Study (SENTINEL)

Mohsen Elalfy, Baba Inusa, David Beneitez, Blanca Xicoy, MD, Maria Soledad Duran Nieto, Andreas Bruederle, Amin Azmon, Amal El-Beshlawy

Blood (2016) 128 (22): 4831.

https://doi.org/10.1182/blood.V128.22.4831.4831

Published: 2016

Journal Articles

Treatment Outcomes in Patients with Transfusional Hemosiderosis Who Received Deferasirox for up to 3 Years: Results from Sentinel Study

Mohsen Elalfy, Baba Inusa, David Beneitez, Blanca Xicoy, MD, Maria Soledad Duran Nieto, Andreas Bruederle, Amin Azmon, Amal El-Beshlawy

Blood (2016) 128 (22): 4834.

https://doi.org/10.1182/blood.V128.22.4834.4834

Published: 2016

Journal Articles

Renal Safety after More Than a Decade of Deferasirox Use in Patients with Transfusional Hemosiderosis

Raffaella Origa, Antonio Piga, MD, Immacolata Tartaglione, MD, Giuseppina Della Corte, Ali El-Ali, Jackie Han, Chiara Castiglioni, Gian Luca Forni, MD

Blood (2016) 128 (22): 2466.

https://doi.org/10.1182/blood.V128.22.2466.2466

Published: 2016

Journal Articles

Long-Term Therapy with Deferasirox in Young Pediatric Patients with Transfusional Hemosiderosis Completing up to 5 Years of Treatment in the Observational E.N.T.R.U.S.T. Study

Elliott Vichinsky, Amal El-Beshlawy, Azzam Alzoebie, Annie Kamdem, MD, Suzanne Koussa, Thirachit Chotsampancharoen, Andreas Bruederle, Jackie Han, Mohsen Elalfy

Blood (2016) 128 (22): 2470.

https://doi.org/10.1182/blood.V128.22.2470.2470

Published: 2016

Journal Articles

Prospective, Multinational/Regional, Non-Interventional Study to Assess Treatment Practices in Anemia Patients Prone to Iron Overload: Results from the 3-Year Transfusional Hemosiderosis Registry (TORS)

Noppadol Siritanaratkul, Jong Wook Lee, Jun Ma, Mustafa Pehlivan, Elena Volodicheva, Qian Jiang, Fatiha Grifi, Bor-Sheng Ko, Raymond Wong, Vernon Louw, Abderrahim Khelif, Ali El-Ali, Jackie Han, Alfonso Losco, Osman Ilhan

Blood (2015) 126 (23): 2152.

https://doi.org/10.1182/blood.V126.23.2152.2152

Published: 2015

Journal Articles

Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study

Ambica Parmar, MD, Heather A Leitch, MD PhD, Richard A. Wells, MD DPhil, Thomas J. Nevill, MD FRCPC, Nancy Y Zhu, MDFRCPC, Karen W.L. Yee, MD, Brian Leber, MD, Mitchell Sabloff, MDM, Eve St-Hilaire, MD, Rajat Kumar, MD, Michelle Geddes, MD FRCPC, John Storring, MD, Andrea Kew, MD, April Shamy, MDM, Mohamed Elemary, MD MSc,PhD, Martha Lenis, Alex Mamedov, Rena Buckstein, MD FRCPC

Blood (2015) 126 (23): 1701.

https://doi.org/10.1182/blood.V126.23.1701.1701

Published: 2015

Journal Articles

Quantitation of Iron in Brain Structures of Children with Sickle Cell Disease and Transfusion Hemosiderosis

R. Clark Brown, MD PhD, Deqiang Qiu, PhD, Laura Hayes, MD, Vaughn Barry, PhD MPH, Richard Jones, PhD

Blood (2014) 124 (21): 1393.

https://doi.org/10.1182/blood.V124.21.1393.1393

Published: 2014

Journal Articles

Role of Magnetic Ressonance Imaging – T2* in Hereditary Hemochromatosis.

Reijane Alves de Assis, MD, Fernando Uliana Kay, MD, Paulo Vidal Campregher, MD, Gilberto Szarf, MD, Fabiana Mendes Conti, MD, Michelli da Silva Diniz, Roberta Sitnik, PhD, Morgani Rodrigues, MD, Ricardo Helman, MD, Marcelo Funari, MD, Nelson Hamerschlak, MD, PhD

Blood (2012) 120 (21): 2096.

https://doi.org/10.1182/blood.V120.21.2096.2096

Published: 2012

Journal Articles

Haemopoietic Improvement Following Iron Chelation for Transfusional Haemosiderosis in Patients with Haematopoietic Neoplasia and Aplastic Anaemia: An Observational Study

Stephen Opat, MBBS(Hons) FRACP FRCPA, Robert Bird, MD, Cecily J Forsyth, FRACP, FRCPA, Jeffrey Szer, MBBS, FRACP, Constantine S. Tam, MBBS, FRACP, FRCPA, Penelope Motum, MB BS PhD FRACP FRCPA, Mark A. Bentley, MBBS FRCPA FRACP

Blood (2011) 118 (21): 5050.

https://doi.org/10.1182/blood.V118.21.5050.5050

Published: 2011

Journal Articles

The Palatability and Tolerability of Deferasirox (Exjade®) Taken with Meals, Different Liquids, or Crushed and Added to Food

Stuart L Goldberg, MD, Patricia Giardina, MD, Joan Parkhurst Cain, MD, Deborah Chirnomas, MD, MPH, Jason Esposito, Carole S. Paley, MD, Elliott Vichinsky, MD

Blood (2010) 116 (21): 5155.

https://doi.org/10.1182/blood.V116.21.5155.5155

Published: 2010

Journal Articles

Deferasirox Improves Liver Pathology In β-Thalassemia Patients with Transfusional Iron Overload

Yves Deugnier, MD, Bruno Turlin, MD, PhD, Victor Dong, MD, Vanessa Giannone, BSN, Yiyun Zhang, PhD, Louis Griffel, MD, Pierre Brissot, MD

Blood (2010) 116 (21): 4274.

https://doi.org/10.1182/blood.V116.21.4274.4274

Published: 2010

Journal Articles

A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox In Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R 2 mri.

Yoo-Hong Min, Hyeoung Joon Kim, MD, PhD, Kyoo-Hyung Lee, M.D., PhD., Jae Hoon Lee, MD, PhD, Hee-Sook Park, Jin Seok Kim, Hyeok Shim, MD, Chu-Myung Seung, Chul Soo Kim, Jooseop Chung, MD, PhD, Myung Soo Hyun, Deog-Yeon Jo, MD, PhD, Chul Won Jung, Sang Kyun Sohn, Hwi-Joong Yoon, MD, PhD, Byung Soo Kim, Young-Don Joo, Chi-Young Park

Blood (2010) 116 (21): 1125.

https://doi.org/10.1182/blood.V116.21.1125.1125

Published: 2010

Journal Articles

Safety of Deferasirox (Exjade®) in Myelodysplastic Syndromes (MDS) and Non-MDS Patients with Transfusional Iron Overload: A Pooled Analysis Focusing On Renal Function.

Mathias Schmid, M. Domenica Cappellini, John B. Porter, Peter L. Greenberg, MD, Tomasz Lawniczek, Sabine Glaser, Victor Dong, Norbert Gattermann, MD, PhD

Blood (2009) 114 (22): 1768.

https://doi.org/10.1182/blood.V114.22.1768.1768

Published: 2009

Journal Articles

Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study.

Alan F. List, Maria R. Baer, David P. Steensma, Azra Raza, Jason Esposito, Noelia Martinez-Lopez, Carole Paley, John Feigert, Emmanuel C. Besa

Blood (2009) 114 (22): 3829.

https://doi.org/10.1182/blood.V114.22.3829.3829

Published: 2009

Journal Articles

A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox in Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R 2 MRI

Blood (2008) 112 (11): 3649.

https://doi.org/10.1182/blood.V112.11.3649.3649

Published: 2008

Journal Articles

Neither Serum Ferritin Nor Number of Red Blood Cell Transfusions Affect Overall Survival in Refractory Anemia with Ringed Sideroblasts.

Cheng E. Chee, MD, David P. Steensma, MD, Curtis A. Hanson, MD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 2454.

https://doi.org/10.1182/blood.V110.11.2454.2454

Published: 2007

Journal Articles

Deferasirox (ICL670; Exjade®) Reduces Serum Ferritin (SF) and Labile Plasma Iron (LPI) in Patients with Myelodysplastic Syndromes (MDS).

Alan F. List, M.R. Baer, D. Steensma, A. Raza, J. Esposito, J. Virkus, J. Feigert, E. Besa, C. Paley

Blood (2007) 110 (11): 1470.

https://doi.org/10.1182/blood.V110.11.1470.1470

Published: 2007

Journal Articles

Latin American Registry of Patients (Pts) with Transfusional Hemosiderosis (Th): The RELATH Study.

Rodolfo Cancado, MD, Ivan Angulo, MD, Zaida Plumacher, MD, Mariela Moreno, MD, Adriana Linares, MD, Juan P. Zarate, MD

Blood (2007) 110 (11): 4013.

https://doi.org/10.1182/blood.V110.11.4013.4013

Published: 2007

Journal Articles

Cytoprotective Effect of ICL670 (Deferasirox) on At20 Endocrine Cells Susceptible to Iron-Evoked Oxidative Damage.

Hava Glickstein, Hanspeter Nick, Zvi Loav Cabantchik

Blood (2006) 108 (11): 3825.

https://doi.org/10.1182/blood.V108.11.3825.3825

Published: 2006

NARROW

Wheatgrass Extract (Mugineic Acid): An Inexpensive and Effective Iron Chelator in Patients with Myelodysyplastic Syndromes

Impact of Age and Type of Underlying Disease on Long-Term Safety and Efficacy in Patients with Transfusional Hemosiderosis Treated with Deferasirox: Results from a 3-Year Non-Interventional Study (SENTINEL)

Treatment Outcomes in Patients with Transfusional Hemosiderosis Who Received Deferasirox for up to 3 Years: Results from Sentinel Study

Renal Safety after More Than a Decade of Deferasirox Use in Patients with Transfusional Hemosiderosis

Long-Term Therapy with Deferasirox in Young Pediatric Patients with Transfusional Hemosiderosis Completing up to 5 Years of Treatment in the Observational E.N.T.R.U.S.T. Study

Prospective, Multinational/Regional, Non-Interventional Study to Assess Treatment Practices in Anemia Patients Prone to Iron Overload: Results from the 3-Year Transfusional Hemosiderosis Registry (TORS)

Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study

Quantitation of Iron in Brain Structures of Children with Sickle Cell Disease and Transfusion Hemosiderosis

Role of Magnetic Ressonance Imaging – T2* in Hereditary Hemochromatosis.

Haemopoietic Improvement Following Iron Chelation for Transfusional Haemosiderosis in Patients with Haematopoietic Neoplasia and Aplastic Anaemia: An Observational Study

The Palatability and Tolerability of Deferasirox (Exjade®) Taken with Meals, Different Liquids, or Crushed and Added to Food

Deferasirox Improves Liver Pathology In β-Thalassemia Patients with Transfusional Iron Overload

A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox In Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R 2 mri.

Safety of Deferasirox (Exjade®) in Myelodysplastic Syndromes (MDS) and Non-MDS Patients with Transfusional Iron Overload: A Pooled Analysis Focusing On Renal Function.

Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study.

A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox in Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R 2 MRI

Neither Serum Ferritin Nor Number of Red Blood Cell Transfusions Affect Overall Survival in Refractory Anemia with Ringed Sideroblasts.

Deferasirox (ICL670; Exjade®) Reduces Serum Ferritin (SF) and Labile Plasma Iron (LPI) in Patients with Myelodysplastic Syndromes (MDS).

Latin American Registry of Patients (Pts) with Transfusional Hemosiderosis (Th): The RELATH Study.

Cytoprotective Effect of ICL670 (Deferasirox) on At20 Endocrine Cells Susceptible to Iron-Evoked Oxidative Damage.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only